POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER
Clinical safety rating
cautionComprehensive clinical and safety monograph for POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER (POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER).
Potassium chloride replaces potassium ions, essential for maintaining cellular membrane potential, nerve impulse conduction, and muscle contraction. Dextrose 5% provides 5% glucose as a caloric source. Lactated Ringer's solution contains electrolytes (sodium, potassium, calcium, chloride) and lactate (bicarbonate precursor) to restore fluid and electrolyte balance.
| Metabolism | Potassium is primarily absorbed and eliminated by the kidneys; not metabolized. Dextrose is metabolized via glycolysis and the Krebs cycle. Lactate is converted to bicarbonate in the liver. |
| Excretion | Primarily renal (>90%) via glomerular filtration and distal tubular secretion; minimal fecal loss (<10%). |
| Half-life | Not applicable; potassium is an electrolyte with no true elimination half-life. In overdose, redistribution from extracellular to intracellular compartments occurs with a half-life of approximately 2-3 hours. |
| Protein binding | Not significantly protein-bound (<5%). |
| Volume of Distribution | 0.3-0.4 L/kg (total body water distribution; potassium is primarily intracellular). |
| Bioavailability | Oral: 90-100% (well-absorbed). Intravenous: 100%. |
| Onset of Action | Intravenous infusion: Immediate upon administration (1-2 minutes). |
| Duration of Action | As long as infusion continues; after cessation, effects last minutes to hours depending on total body potassium balance. |
| Molecular Weight | 74.55 |
IV infusion of 10 mEq/hour, not to exceed 20 mEq/hour; maximum 40 mEq per dose, typically administered in 100-1000 mL solution over 2-4 hours.
| Dosage form | INJECTABLE |
| Renal impairment | GFR 30-50 mL/min: reduce dose by 25-50%; GFR 10-29 mL/min: reduce dose by 50-75%; GFR <10 mL/min: avoid use unless plasma potassium is severely depleted and ECG monitoring is available. |
| Liver impairment | No specific adjustment for Child-Pugh class A or B; use with caution in severe hepatic impairment (Child-Pugh class C) due to increased risk of hyperkalemia from reduced hepatic clearance. |
| Pediatric use | IV infusion of 0.5-1 mEq/kg per dose, not to exceed 40 mEq/day; administer at a rate of 0.3-0.5 mEq/kg/hour with continuous ECG monitoring. |
| Geriatric use | Initiate at low end of dosing range (0.5 mEq/kg/h); monitor renal function and serum potassium closely due to age-related decline in renal function. |
| 1st trimester | Potassium chloride and lactated Ringer's solution are generally considered safe when used as indicated. Potassium is essential for maternal and fetal cellular function; however, hyperkalemia or hypokalemia should be avoided. Dextrose may cause maternal hyperglycemia, which is associated with fetal risks. Use only if clearly needed. |
| 2nd trimester | Same as first trimester. Monitor serum potassium and glucose levels. Avoid excessive dextrose administration to prevent fetal hyperinsulinism and neonatal hypoglycemia. |
| 3rd trimester | Same as second trimester. During labor, lactated Ringer's solution is commonly used for fluid resuscitation. Potassium supplementation should be guided by serum levels to avoid cardiac arrhythmias. |
Clinical note
Comprehensive clinical and safety monograph for POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER (POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER).
| Placental transfer | Potassium crosses the placenta by active transport, maintaining fetal potassium levels slightly higher than maternal. Dextrose crosses freely via facilitated diffusion. Lactated Ringer's components (sodium, chloride, lactate) also cross the placenta. No adverse fetal effects are expected with therapeutic use. |
| Breastfeeding | Potassium chloride and lactated Ringer's components are normal constituents of human milk and are not expected to cause adverse effects in a nursing infant when used therapeutically. Excretion into milk is minimal and not clinically significant. Dextrose is also a normal milk constituent. Use caution with high doses of potassium, as theoretical risk of hyperkalemia in infant exists if maternal levels are markedly elevated. |
| Lactation Rating | Safe |
| Teratogenic Risk | Potassium chloride is a normal constituent of body fluids and is not teratogenic at physiological levels. In pregnancy, hyperkalemia or hypokalemia may cause adverse fetal effects; however, at therapeutic doses, no increased risk of congenital anomalies has been reported across trimesters. There is no evidence of teratogenicity in animal studies. |
| Fetal Monitoring | Monitor serum potassium levels, renal function, and acid-base balance. Continuous ECG monitoring recommended during intravenous administration due to risk of arrhythmias from hyperkalemia. In pregnancy, monitor fetal heart rate during infusion due to potential maternal electrolyte disturbances affecting fetal well-being. |
| Fertility Effects | No adverse effects on fertility have been reported with potassium chloride at therapeutic doses. Electrolyte imbalances (hyper- or hypokalemia) may secondarily affect reproductive function, but direct fertility impairment is not established. |
■ FDA Black Box Warning
NO BLACK BOX WARNING
| Serious Effects |
HyperkalemiaSevere renal impairment with oliguria or anuriaAddison's diseaseAcute dehydration with heat crampsHyperchloremiaPotassium-sparing diuretic therapy (concurrent use)Hyperlactatemia or severe metabolic acidosis (due to lactate component)Hyperglycemia uncontrolled (relative contraindication for dextrose)
| Precautions | Hyperkalemia risk, especially in renal impairment, Monitor serum potassium levels frequently, Use with caution in patients with cardiac disease, conduction disorders, or medullary sponge kidney, Avoid in patients with metabolic alkalosis, Risk of volume overload in patients with heart failure or renal impairment |
| Food/Dietary | No direct food interactions. However, patients should avoid excessive dietary potassium intake from high-potassium foods (e.g., bananas, oranges, spinach, potatoes) without medical guidance, especially if renal impairment exists. |
| Clinical Pearls | This combination provides potassium chloride 40 mEq in 1 L of D5LR, delivering 40 mEq K+, 5% dextrose, and lactated Ringer's solution. Administration rate should not exceed 10 mEq/hour via peripheral IV or 20 mEq/hour via central line to avoid hyperkalemia. Monitor serum potassium, glucose, and renal function. Contraindicated in severe hyperkalemia, anuria, or hypovolemic shock. Use with caution in metabolic alkalosis as lactate may exacerbate. |
| Patient Advice | This medication is given through a vein to correct low potassium levels and provide fluids and sugar. · Tell your healthcare provider if you have kidney problems, heart disease, or diabetes. · Report any symptoms of high potassium such as muscle weakness, irregular heartbeat, or tingling sensations. · Do not stop or change the infusion rate unless instructed by your provider. · Inform your provider if you are pregnant, breastfeeding, or on any other medications. |
Loading safety data…